arrow
A

Antonio Galvano

University of Palermo
H指数:32
被引数:3,114

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An intriguing journey into the hereditary syndromes predisposing to endometrial cancer: more than believed

一个引人入胜的旅程,深入探讨易感子宫内膜癌的遗传综合征:超过预期的认知

2026-03-190
OA
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer

液体活检在精准肿瘤学中的最新进展:新兴生物标志物及其在肺癌中的临床应用

2025-08-050
PRE
Smaller, cheaper, faster: where next for liquid biopsies?

更小、更便宜、更快:液体活检的未来走向何方?

2025-07-140
PRE
Clinical Validation of a Machine Learning-Based Biomarker Signature to Predict Response to Cytotoxic Chemotherapy Alone or Combined with Targeted Therapy in Metastatic Colorectal Cancer Patients: A Study Protocol and Review
2025-02-190
OAAI
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study

晚期非小细胞肺癌患者的一线治疗中循环细胞外囊泡的动态变化: LEXOVE前瞻性研究

2025-01-090
OA
Scientific Communication and oncology - The bridge between knowledge and patients

科学传播与肿瘤学 -- 知识与患者之间的桥梁

2024-12-010
OAAI
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients

基于扩增子的下一代测序在一线非小细胞肺癌患者中ctDNA的临床应用

2024-09-271
OAAI
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors
2024-09-050
OAAI
Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)

上皮性卵巢癌(EOC)患者携带同源重组缺陷(HRD)突变特征时的妊娠与流产情况

2024-09-010
PRE
Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?

血浆外泌体在免疫系统与遗传性卵巢癌相互作用中的作用:机遇还是挑战?

2024-09-010
PRE
Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?

基线外泌体递送的PD-1、PD-L1、泛-BTN3As和BTN3A1在晚期胆管癌患者中的预后相关性:免疫检查点能否作为预测生存的哨兵?

2024-09-010
PRE
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis

PARP抑制剂在卵巢癌整体管理中的影响: 系统评价和网络荟萃分析

2024-01-012
OAAI
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?

非BRCA相关同源重组缺陷肿瘤患者的治疗诊断生物标志物和PARP抑制剂有效性: 仍在透过肮脏的玻璃窗看?

2023-12-0111
OAAI